Randomized, Double-blind, Parallel Controlled, Multicenter Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Arotinib Capsules and Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer After Immune Resistance
Latest Information Update: 29 Sep 2024
At a glance
- Drugs Benmelstobart (Primary) ; Catequentinib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 19 Sep 2024 Planned End Date changed from 30 Mar 2026 to 30 Dec 2028.
- 19 Sep 2024 Planned primary completion date changed from 30 Sep 2025 to 30 Dec 2027.
- 27 Nov 2023 New trial record